Triple Hair Group, a company which specializes in the development of innovative treatments for androgenic alopecia, secures $4million in funding.
Supporters included Investissement Québec, Prevail Partners, and the Québec government via its Impulsion PME programme (which includes a biopharmaceutical component). With the money, the business plans to expedite Phase III clinical trials for Therapy-07, its signature prescription medicine, across a number of nations.
Triple Hair is a biotechnology firm headed by CEO and President Jean-Philippe Gravel. The company specialises in creating cutting-edge treatments for alopecia in both men and women. It seeks to supply clinically validated, effective over-the-counter and prescription hair restoration treatments to the underserved market.
Read also – [Funding News] NYC-based Authentic Secures $11Million in Series A Round Funding
Additionally, the business offers its proprietary, drug-free solutions under the trademarks Plenty NaturalTM for women and RIZNTM for men, which help people with mild to moderate alopecia prevent hair loss and restore hair density. Early-stage hair loss sufferers can readily obtain natural hair growth remedies without a prescription thanks to RIZNTM and Plenty NaturalTM.
Jean-Philippe Gravel said: “These funds will notably enable us to prepare the Phase III clinical trials planned for Therapy-07. We have Health Canada’s approval to begin our Phase III clinical trials, and awaiting approvals from other jurisdictions, notably the US and Europe. As soon as we receive these approvals, we will proceed to finalize our capital structure and begin clinical trials in several countries.”
About Triple Hair
Triple Hair is making significant progress in creating treatments for hair loss and thinning hair with effective dense regrowth, with the goal of becoming a global leader in clinical research for androgenetic alopecia.
